Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

PMOS rethink reframes a common hormone disorder as a whole-body disease

18

Jun 2026

PMOS rethink reframes a common hormone disorder as a whole-body disease

A new review reframes PCOS, now proposed as PMOS, as a systemic endocrine and metabolic disorder shaped by genetic, epigenetic, ovarian, metabolic, and neuroendocrine pathways. It highlights why inconsistent diagnosis and symptom-focused care have limited progress, while targeted therapies, biomarkers, machine learning, and organ-on-chip models may support more personalized treatment.

New biological age tools could reveal health risks before symptoms appear

18

Jun 2026

New biological age tools could reveal health risks before symptoms appear

A JCI review traces biological age measurement from functional tests and blood biomarkers to epigenetic, proteomic, imaging, wearable, and AI-based clocks. It finds that these tools can improve risk prediction beyond chronological age, but standardization, interpretability, and prospective validation are needed before routine clinical use.

Aircraft emissions could double air pollution deaths by 2040

18

Jun 2026

Aircraft emissions could double air pollution deaths by 2040

Scenario-based modeling projects that aviation-related air pollution could drive a major rise in premature deaths by 2040, mainly through PM2.5 and ozone exposure. The study estimates that aircraft emissions caused 33,900 PM2.5-related deaths and 24,600 ozone-related deaths in 2019, with baseline 2040 deaths projected to more than double.

AI diagnostic errors raise hospital blame unless doctors stay deeply involved

17

Jun 2026

AI diagnostic errors raise hospital blame unless doctors stay deeply involved

A two-study vignette experiment found that people attributed more responsibility to hospitals and were more likely to consider filing a complaint or taking legal action when missed diagnoses involved AI rather than a physician alone. Interactive physician involvement reduced negative reactions, while autonomous or sequential AI-human collaboration did not meaningfully improve responses compared with AI-only diagnosis.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.